DNX/BioClin merger to create CRO with $40 mil. in 1995 revenues.
DNX/BIOCLIN MERGER TO CREATE CRO WITH $40 MIL. IN ANNUAL REVENUES, the contract research organizations announced Aug. 19. DNX generated revenues of $26.5 mil. in 1995 through its pre-clinical drug development services. BioClin generated $14.3 mil. in revenues last year from its Phase I-IV clinical research business. The combined company will have over 300 pharmaceutical clients and 450 employees worldwide.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth